UN Panel Report: Positions Still Polarized Over Medicines Access Barriers
Executive Summary
The report by the independent panel shows that the companies that develop and produce medicines, and the non-governmental organizations working on health issues at local level, still disagree fundamentally on the best way to go about improving access to those medicines. While R&D firms are skeptical of the report’s recommendations, the feeling among NGOs seems to be that this report represents something of a landmark development in the access debate.
You may also be interested in...
$1–2 Per Month Could Help Solve Access To Essential Medicines Problem, Experts Say
Just $13 a year could provide a basic set of affordable medicines to all people in low- and middle-income countries, experts commissioned by The Lancet say in a report calling for better access to essential medicines. But views differ as to whether all the recommendations in the report are appropriate or go far enough to address the roots of the problem.
$1–2 Per Month Could Help Solve Access To Essential Medicines Problem, Experts Say
Just $13 a year could provide a basic set of affordable medicines to all people in low- and middle-income countries, experts commissioned by The Lancet say in a report calling for better access to essential medicines. But views differ as to whether all the recommendations in the report are appropriate or go far enough to address the roots of the problem.
MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.